DE60115000D1 - Die Verwendung von Prostaglandin F Analoga zur Herstellung von Zusammensetzungen für die Behandlung von Haarausfall. - Google Patents

Die Verwendung von Prostaglandin F Analoga zur Herstellung von Zusammensetzungen für die Behandlung von Haarausfall.

Info

Publication number
DE60115000D1
DE60115000D1 DE60115000T DE60115000T DE60115000D1 DE 60115000 D1 DE60115000 D1 DE 60115000D1 DE 60115000 T DE60115000 T DE 60115000T DE 60115000 T DE60115000 T DE 60115000T DE 60115000 D1 DE60115000 D1 DE 60115000D1
Authority
DE
Germany
Prior art keywords
compositions
hair loss
analogs
prostaglandin
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60115000T
Other languages
English (en)
Other versions
DE60115000T2 (de
Inventor
Anthony Delong
Mcmillan Mciver
Scott Youngquist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Durham
Duke University
Original Assignee
University of Durham
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22714441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60115000(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Durham, Duke University filed Critical University of Durham
Application granted granted Critical
Publication of DE60115000D1 publication Critical patent/DE60115000D1/de
Publication of DE60115000T2 publication Critical patent/DE60115000T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60115000T 2000-03-31 2001-03-30 Die Verwendung von Prostaglandin F Analoga zur Herstellung von Zusammensetzungen für die Behandlung von Haarausfall. Expired - Lifetime DE60115000T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19364500P 2000-03-31 2000-03-31
US193645P 2000-03-31
PCT/US2001/010370 WO2001074315A2 (en) 2000-03-31 2001-03-30 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

Publications (2)

Publication Number Publication Date
DE60115000D1 true DE60115000D1 (de) 2005-12-22
DE60115000T2 DE60115000T2 (de) 2006-08-17

Family

ID=22714441

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60115000T Expired - Lifetime DE60115000T2 (de) 2000-03-31 2001-03-30 Die Verwendung von Prostaglandin F Analoga zur Herstellung von Zusammensetzungen für die Behandlung von Haarausfall.

Country Status (10)

Country Link
US (10) US20020172693A1 (de)
EP (1) EP1267807B1 (de)
JP (7) JP2003528899A (de)
CN (3) CN100384425C (de)
AT (1) ATE309775T1 (de)
AU (1) AU2001253039A1 (de)
CA (1) CA2401731C (de)
DE (1) DE60115000T2 (de)
ES (1) ES2252215T3 (de)
WO (1) WO2001074315A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010108316A (ko) 1999-03-05 2001-12-07 데이비드 엠 모이어 Ｃ16 불포화된 ｆｐ-선택적 프로스타글란딘 유사체
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
JP2004538288A (ja) * 2001-07-25 2004-12-24 アルコン，インコーポレイティド プロスタグランジンアナログの局所的適用を包含する、発毛促進のための方法
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US20030199590A1 (en) * 2002-07-25 2003-10-23 Cagle Gerald D Prostaglandin analogues for promotion of hair growth
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
EP1812017A2 (de) * 2004-10-21 2007-08-01 Duke University Ophthalmologische arzneimittel
WO2007023841A1 (ja) * 2005-08-25 2007-03-01 Taisho Pharmaceutical Co., Ltd. 発毛剤組成物
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US7879910B1 (en) * 2006-10-10 2011-02-01 Jan Marini Skin Research, Inc. Compositions and methods for promoting lush hair growth
US20080097070A1 (en) * 2006-10-19 2008-04-24 L'oreal Aqueous polyamine-containing systems for water-insoluble materials
US20080096782A1 (en) * 2006-10-19 2008-04-24 L'oreal Aqueous systems containing phospholipid, surfactant and phosphate ester for water-insoluble materials
ITMI20071073A1 (it) * 2007-05-25 2008-11-26 Ctg Pharma S R L Composizioni farmaceutiche di prostaglandine
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
WO2009045908A2 (en) * 2007-09-28 2009-04-09 Cayman Chemical Company A method for screening of prostaglandin compounds comprising an optimal formulation for the enhancement of hair growth and the stimulation of follicular anagen and formulations resulting therefrom
JP2011502152A (ja) * 2007-10-31 2011-01-20 パメラ リプキン プロスタグランジン類似体組成物及び上皮関連症状の治療方法
WO2010039535A1 (en) * 2008-09-23 2010-04-08 Meta Cosmetics, Llc Compositions and methods to treat epithelial-related conditions
US7744995B2 (en) * 2007-12-18 2010-06-29 Toyota Motor Engineering & Manufacturing North America, Inc. Multi-layer coatings for substrates
WO2009140430A1 (en) * 2008-05-14 2009-11-19 Peter Thomas Roth Labs, Llc Prostaglandin based compositions and method of use thereof
EP2153836A1 (de) * 2008-08-04 2010-02-17 Polichem S.A. Filmbildende flüssige Formulierungen zur Wirkstofffreisetzung im Haar und auf der Kopfhaut
CN102143753B (zh) * 2008-09-04 2013-07-03 参天制药株式会社 含有15,15-二氟前列腺素F2α衍生物作为有效成分的毛发生长促进剂
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
WO2010064203A1 (en) 2008-12-02 2010-06-10 L'oreal Combination of reduced glutathione and amino acids for improving the quality of the hair in women
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
CA2769512C (en) 2009-07-29 2019-07-09 Duke University Compositions comprising fp receptor antagonists and their use for inhibiting hair growth
FR2949052B1 (fr) 2009-08-13 2015-03-27 Oreal Procede de traitement cosmetique du cuir chevelu.
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
MX361709B (es) 2009-11-09 2018-12-07 Allergan Inc Composiciones y metodos para estimular el crecimiento del cabello.
US9149484B2 (en) * 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US20120184894A1 (en) * 2010-12-31 2012-07-19 Mir Imran Patches and Methods for the Transdermal Delivery of Agents to Treat Hair Loss
EP2665481B1 (de) 2011-01-19 2016-03-30 Topokine Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung des stoffwechselsyndroms
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2013158649A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
US20150164765A1 (en) * 2012-05-17 2015-06-18 Steven G. Yoelin Compositions and methods for hair growth
EP2857002A4 (de) * 2012-05-30 2015-12-09 Asahi Glass Co Ltd Zusammensetzung für haarwachstum
NO2753788T3 (de) 2013-05-10 2018-06-16
WO2014182908A1 (en) * 2013-05-10 2014-11-13 Topical Solutions, Inc. Compositions and methods for treating nails, claws, and hoofs
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
CA2927730A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP2017502089A (ja) * 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ 偏頭痛の処置
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
WO2016083891A1 (en) * 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents
WO2017068604A1 (en) * 2015-10-22 2017-04-27 Deltahex Innovation Pvt. Ltd Hair growth stimulant and preparation method thereof
US11185487B2 (en) * 2015-12-28 2021-11-30 Johnson & Johnson Consumer Inc. Hair growth composition and method
US10136438B2 (en) * 2016-01-22 2018-11-20 Space Systems/Loral, Inc. Flexible bandwidth assignment to spot beams
DE102016110381A1 (de) * 2016-06-06 2017-12-07 Edwin Kohl Kosmetische Zusammensetzung, insbesondere zur Förderung des Haarwuchses
SG11201901137UA (en) 2016-08-12 2019-03-28 Silk Technologies Ltd Silk-derived protein for treating inflammation
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
CA3052466A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
KR101831947B1 (ko) * 2017-09-20 2018-02-23 아주대학교산학협력단 아토르바스타틴을 유효성분으로 포함하는 난청의 예방 또는 치료용 조성물
US11185530B2 (en) 2017-03-09 2021-11-30 Ajou University Industry-Academic Cooperation Foundation Composition for preventing or treating hearing loss, containing atorvastatin as active ingredient
WO2019113210A1 (en) 2017-12-05 2019-06-13 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
JP2022507888A (ja) 2018-11-21 2022-01-18 ケース ウェスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物及び方法
PT3886799T (pt) 2019-08-07 2023-12-22 Aneira Pharma Inc Composições para o tratamento da queda de cabelo
JP2023527279A (ja) 2020-05-20 2023-06-28 ロデオ・セラピューティクス・コーポレイション 短鎖デヒドロゲナーゼ活性を調節する組成物及び方法
US11850300B2 (en) 2022-03-17 2023-12-26 Rally Guide Topical lotion composition, methods of use, and methods of preparation

Family Cites Families (323)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37913A (en) 1863-03-17 Improvement in sewing-machines
US13294A (en) 1855-07-17 Improved apparatus for cooling repeating fire-arms
US146439A (en) 1874-01-13 Improvement in pruning-shears
US37914A (en) 1863-03-17 Improved automatic nose-bag
DE1617477U (de) 1950-09-27 1950-12-14 Heinrich Dressel Radhalter fuer raeder, beispielsweise fuer kinderwagen und kleinfahrzeuge.
US3069322A (en) 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
US3776938A (en) 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US3839409A (en) 1958-05-28 1974-10-01 Kemiska Inst Karolinska I Pge3 esters and alkanoates
US3776939A (en) 1958-05-28 1973-12-04 S Bergstrom Dihydro-pgf1a
DE1801750U (de) 1959-07-07 1959-12-10 H L Wahrendorf Betonwerk Trog zur aufnahme des weichengestaenges von eisenbahngleisen.
US3382248A (en) 1965-11-01 1968-05-07 Upjohn Co 6-amino-4, 5-di(substituted amino)-1, 2-dihydro-1-hydroxy-2-iminopyrimidines
US3524867A (en) 1966-06-06 1970-08-18 Upjohn Co Process for producing cyclopenta (b)pyrans
US3435053A (en) 1966-06-06 1969-03-25 Upjohn Co Cyclopenta(b)pyrans
US3538120A (en) 1967-05-22 1970-11-03 Ciba Geigy Corp Cyclopentyl-alkanoic acids
US3636120A (en) 1967-10-09 1972-01-18 Upjohn Co Prostaglandin e primary alcohols
GB1285371A (en) 1968-08-29 1972-08-16 Upjohn Co Improvements in or relating to therapeutic methods using prostaglandins
GB1251750A (de) 1968-11-12 1971-10-27
DE1910561A1 (de) 1969-03-01 1970-09-10 Herten Dr Med Kurt Mittel zur Verhuetung von Haarausfall
BE755555A (fr) 1969-09-02 1971-03-01 Richardson Merrell Inc Derives de quinoxaline
US3882241A (en) 1969-12-01 1975-05-06 Upjohn Co Use of prostaglandins E and F for prevention of pregnancy in humans
US3896156A (en) 1970-06-30 1975-07-22 Upjohn Co Dihydroprostaglandin e, analogs
IT1012505B (it) 1970-09-28 1977-03-10 Imes C Spa Estratto di ricci di mare
GB1324737A (en) 1970-11-02 1973-07-25 Upjohn Co Prostaglandins and the preparation thereof
US4124720A (en) 1970-11-09 1978-11-07 Wenmaekers Georges E J Therapeutic hydrodispersible emulsion
JPS5212919Y2 (de) 1971-06-14 1977-03-23
BE791369A (fr) 1971-11-16 1973-05-14 American Cyanamid Co Cyanurates de tris-(meta-hydroxybenzyle) faisant l'objet d'un empechement sterique et utilisables comme anti-oxydants
JPS525744Y2 (de) 1972-03-18 1977-02-05
US3798275A (en) 1972-04-05 1974-03-19 Ciba Geigy Corp Etherified mercapto-methoxyamines
US4304907A (en) 1972-05-10 1981-12-08 The Upjohn Company Bicyclo lactone intermediates for prostaglandin analogs
US3974213A (en) 1972-07-13 1976-08-10 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins
US4011262A (en) 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
JPS4969636U (de) 1972-09-29 1974-06-18
JPS5220141Y2 (de) 1972-10-13 1977-05-10
US3882245A (en) 1972-11-01 1975-05-06 Upjohn Co Use of prostaglandins in combating shock
DD118856A5 (de) 1972-11-08 1976-03-20
IL43571A (en) 1972-11-08 1977-08-31 Pfizer Omega-pentanorprostaglandins and their preparation
US3984424A (en) 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
US4024179A (en) 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
US4152527A (en) 1972-11-08 1979-05-01 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
JPS4993342U (de) 1972-12-05 1974-08-13
JPS5253841Y2 (de) 1972-12-12 1977-12-07
JPS49100071U (de) 1972-12-20 1974-08-28
JPS49101356U (de) 1972-12-20 1974-08-31
JPS5320995Y2 (de) 1972-12-23 1978-06-02
JPS49101356A (de) 1973-02-07 1974-09-25
JPS5720305B2 (de) 1973-02-28 1982-04-27
US3984455A (en) 1973-07-16 1976-10-05 The Upjohn Company Prostaglandin E1 analogs
JPS5118118Y2 (de) 1973-07-17 1976-05-14
FR2239458A1 (en) 1973-07-31 1975-02-28 Aries Robert Prostaglandin amides - with antilipolytic, gonadotrophic, luteolytic, hypotensive and other activities associated with prostaglandins
DE2365101A1 (de) 1973-12-21 1975-07-10 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
US3931282A (en) 1974-02-21 1976-01-06 Syntex (U.S.A.) Inc. 11α-Hydroxymethyl prostaglandins
US3928588A (en) 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
DE2416193C2 (de) 1974-04-03 1985-08-14 Hoechst Ag, 6230 Frankfurt Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
GB1458315A (en) 1974-04-22 1976-12-15 Ici Ltd Prostanoic acid derivatives
JPS50142539U (de) 1974-05-13 1975-11-25
JPS50157344U (de) 1974-06-12 1975-12-26
DE2460990A1 (de) 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
JPS5186449U (de) 1974-12-30 1976-07-10
GB1507211A (en) 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
US3934013A (en) 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition
US4217360A (en) * 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
GB1506816A (en) 1975-03-31 1978-04-12 Upjohn Co Prostaglandins
DE2517771A1 (de) * 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
JPS5328160Y2 (de) 1975-05-16 1978-07-15
GB1520522A (en) 1975-06-16 1978-08-09 Ono Pharmaceutical Co 16-methyleneprostaglandins
ES449162A1 (es) 1975-06-23 1977-12-16 Syntex Inc Un procedimiento para la preparacion de un compuesto racemi-co u 8r-antimerico.
US4005133A (en) 1975-10-14 1977-01-25 The Upjohn Company PGF2.sub.α, L-Arginine salt
US4128577A (en) 1975-12-29 1978-12-05 The Upjohn Company 15-Methyl- and 16-phenoxy-PGF2 α, amides
US4158667A (en) 1976-02-04 1979-06-19 The Upjohn Company 6-Keto PGF analogs
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4596812A (en) 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4051238A (en) 1976-06-03 1977-09-27 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
US4268522A (en) 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
DE2635985A1 (de) 1976-08-06 1978-02-09 Schering Ag Prostansaeurederivat und verfahren zu ihrer herstellung
DE2737807A1 (de) 1976-08-27 1978-03-09 Pfizer C tief 1 -p-biphenylester von omega-pentanorprostaglandinen
DE2737808A1 (de) 1976-08-27 1978-03-16 Pfizer 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
US4123441A (en) 1976-09-22 1978-10-31 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4499293A (en) 1976-09-22 1985-02-12 The Upjohn Company PGI2 Salts
US4089885A (en) 1976-11-05 1978-05-16 American Home Products Corporation Prostaglandin derivatives
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4178457A (en) 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4206151A (en) 1978-12-21 1980-06-03 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
GB2048254B (en) 1979-04-02 1983-05-25 Upjohn Co 19,20 -didehydro-19-hydroxy and 19-oxo-prostaglandin derivatives
JPS5829710Y2 (ja) 1979-05-25 1983-06-29 スガツネ工業株式会社 錠前
US4225508A (en) 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-PGI2 compounds
US4225507A (en) 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-19-methyl-PGI2 compounds
US4296504A (en) 1980-07-07 1981-10-27 Lawson Daniel C Toilet seat lock
JPS6032763Y2 (ja) 1980-09-06 1985-09-30 日興エンジニアリング株式会社 液体充填装置
JPH0222226Y2 (de) 1981-02-04 1990-06-14
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4543353A (en) 1981-11-27 1985-09-24 Farmitalia Carlo Erba S.P.A. Ester and amide derivatives of 13,14-didehydro prostaglandins
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4912235A (en) 1983-12-22 1990-03-27 Syntex (U.S.A.) Inc. Processes and intermediates for making 16-phenoxy- and 16-substituted phenoxy-prostatrienoic acid derivatives and their stereoisomers
WO1986000616A1 (en) 1984-07-13 1986-01-30 Gail Sansone Bazzano Substituted pyrimidine oxides useful for hair growth promotion
JPS6134778U (ja) 1984-07-31 1986-03-03 株式会社明電舎 電気機器収納箱
JPS6147459A (ja) 1984-07-31 1986-03-07 シンテツクス（ユー・エス・エイ）インコーポレイテツド １１−置換−１６−フエノキシプロスタトリエン酸誘導体
JPS61126069A (ja) 1984-11-21 1986-06-13 Res Dev Corp Of Japan プロスタグランジン誘導体
JPS61218510A (ja) * 1985-03-22 1986-09-29 Dai Ichi Seiyaku Co Ltd 毛髪用剤
US5863948A (en) 1985-06-14 1999-01-26 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US4704386A (en) 1985-08-29 1987-11-03 G. D. Searle & Co. 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US4883819A (en) 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
FI872552A (fi) * 1986-06-09 1987-12-10 American Cyanamid Co Prostaglandinkomposition foer lokalt bruk.
US5041439A (en) * 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US5663203A (en) 1986-09-11 1997-09-02 Schering Aktiengesellschaft Agents containing prostacyclin derivatives for topical application
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5219885A (en) 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
JPS63211231A (ja) 1987-02-27 1988-09-02 Sumitomo Pharmaceut Co Ltd 雄性不妊動物の治療剤
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
GB8713747D0 (en) * 1987-06-12 1987-07-15 Unilever Plc Skin treatment composition
US5166178B1 (en) 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
ES2052735T3 (es) 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
SE8703854D0 (sv) 1987-10-07 1987-10-07 Pharmacia Ab Prostaglandinderivat for behandling av glaukom eller okuler hypertension
AU619543B2 (en) 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
DE03014533T1 (de) 1988-09-06 2004-07-15 Pharmacia Ab Prostaglandinderivative zur Behandlung von Glaukom oder okuläre Hypertension
US5321128A (en) 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) * 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5194429A (en) 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US4968812A (en) 1989-06-23 1990-11-06 Shell Oil Company Spirolactonelactams
JPH0737389B2 (ja) 1989-08-29 1995-04-26 久光製薬株式会社 プロスタグランジンｅ１含有の軟膏剤
CA1339132C (en) 1989-09-12 1997-07-29 Johan W. Stjernschantz Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
JPH0627942Y2 (ja) 1989-12-14 1994-07-27 松下電器産業株式会社 ヒューズホルダー付コンデンサー
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
US5063057A (en) 1990-09-26 1991-11-05 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic capsules
US5302617A (en) 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
DE4024347A1 (de) 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
JPH04300833A (ja) 1991-03-29 1992-10-23 Green Cross Corp:The プロスタグランジンｅ１　含有脂肪乳剤充填噴霧剤
US5378840A (en) 1992-04-16 1995-01-03 G. D. Searle & Co. Substituted dibenzoxazepine compounds
US5312832A (en) 1991-05-17 1994-05-17 Allergan, Inc. Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives
US5288754A (en) 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5641494A (en) * 1992-03-20 1997-06-24 Janssen Pharmaceutica N.V. Agent for regulating the greasiness of the skin
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5422371A (en) 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
JP3102141B2 (ja) 1992-05-29 2000-10-23 東レ株式会社 養毛育毛剤
US5817694A (en) * 1992-06-08 1998-10-06 New Pharma International Corp. 16-methyl-11,16-dihydroxy-9-oxoprost-2,13-dien-1-oic acid and derivatives
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
ES2105333T3 (es) 1992-10-13 1997-10-16 Alcon Lab Inc Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.
US5332730A (en) 1992-10-16 1994-07-26 Allergan, Inc. Azido derivatives of cyclopentane heptanoic or heptenoic acid
US5340813A (en) 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
DE4238830A1 (de) 1992-11-17 1994-05-19 Anton Felder Verfahren zum hydraulischen Verzweigen einer offenen Strömung sowie hydraulisch arbeitende Kanalverzweigung
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5395932A (en) 1993-04-30 1995-03-07 G. D. Searle & Co. 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5985597A (en) * 1993-05-26 1999-11-16 Merck Frosst Canada, Inc. DNA encoding prostaglandin receptor EP1
US5869281A (en) 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
CA2165953C (en) 1993-06-25 2003-08-19 Mark Abramovitz Prostaglandin receptor ep3 and dna encoding it
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5516652A (en) 1993-10-06 1996-05-14 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor IP
FR2711060B1 (fr) 1993-10-13 1995-11-17 Oreal Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.
SE9303444D0 (sv) * 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
WO1995011033A1 (en) 1993-10-22 1995-04-27 Commonwealth Scientific And Industrial Research Organisation Polyoxometallates in the treatment of flavivirus infections
SE9303627D0 (sv) 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
US5431881A (en) 1993-12-10 1995-07-11 Palacios; Henry J. Treatment of hair loss and dermatological problems
ES2147836T3 (es) * 1993-12-20 2000-10-01 Fujisawa Pharmaceutical Co Derivados de 4,5-diariloxazol.
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5458883A (en) 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
AU714054B2 (en) * 1995-01-06 1999-12-16 Toray Industries, Inc. Benzene-fused heterocyclic derivatives and use of the same
WO1996023066A2 (en) * 1995-01-26 1996-08-01 Merck Frosst Canada Inc. Prostaglandin receptor, dp
FR2730811B1 (fr) 1995-02-17 1997-03-21 Oreal Procede pour diagnostiquer et/ou suivre l'evolution d'un desordre capillaire et/ou mesurer l'efficacite d'un traitement applique pour combattre un desordre capillaire
US5885766A (en) * 1995-02-17 1999-03-23 Societe L'oreal S.A. Method of screening of substances for their effect on the expression of mediators of inflammation in a hair follicle
DE69613693T2 (de) 1995-05-18 2002-05-16 Allergan Sales Inc 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
US6169111B1 (en) * 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
EP0778269B1 (de) 1995-06-26 2000-09-27 Teijin Limited Prostaglandine und verfahren zu deren herstellung
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
HUP9601442A3 (en) * 1995-07-25 1999-03-29 Panacea Biotec Ltd Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
US5661178A (en) 1995-09-01 1997-08-26 Allergan Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
AU7271996A (en) 1995-10-23 1997-05-15 Queen's University At Kingston Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5866602A (en) 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
EP0869794B1 (de) 1995-12-22 2004-08-11 Alcon Laboratories, Inc. Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel
WO1997023225A1 (en) 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5814660A (en) 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
AU1138097A (en) 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of prostaglandins and miotics for lowering intraocular pressure
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5703108A (en) 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
US5658897A (en) 1996-04-08 1997-08-19 Allergan Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents
US5990168A (en) 1996-04-18 1999-11-23 Alberta Cancer Board Methods and compositions for the treatment of ataxia telangiectasia
JP3049593B2 (ja) * 1996-05-01 2000-06-05 株式会社ビメーク 育毛・養毛剤
WO1997047595A1 (fr) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Antagoniste de l'endotheline
WO1998000100A1 (en) 1996-07-03 1998-01-08 The Board Of Regents Of The University Of Oklahoma Enhancement of skin pigmentation by prostaglandins
US5792851A (en) 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter
WO1998012175A1 (fr) 1996-09-17 1998-03-26 Asahi Glass Company Ltd. Derives de prostaglandine fluores et medicaments
JP4004109B2 (ja) 1996-09-17 2007-11-07 参天製薬株式会社 含フッ素プロスタグランジン誘導体および医薬
US5827508A (en) 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
AU734789B2 (en) 1996-11-01 2001-06-21 Alcon Laboratories, Inc. Use of a combination of carbonic anhydrease inhibitors and prostaglandins for treating glaucoma
US6353000B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
EP0944593A2 (de) 1996-11-12 1999-09-29 Alcon Laboratories, Inc. $i(CIS)-$g(D)?4 ANALOGA VON PROSTAGLANDINEN ALS AUGENDRUCKSENKENDE MITTEL
US6353014B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension
ATE202557T1 (de) 1996-11-12 2001-07-15 Alcon Lab Inc 15-fluoro-prostaglandine als augendrucksenkende mittel
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
NZ335770A (en) 1996-12-20 2005-01-28 Pfizer Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists such as tetrazolyl or carboxylic acid derivatives
JPH10265454A (ja) * 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
CA2279967C (en) * 1997-02-04 2006-08-22 Murray A. Johnstone Method of enhancing hair growth
EP1008588B1 (de) 1997-02-10 2003-04-16 Ono Pharmaceutical Co., Ltd. 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
CN1224354A (zh) 1997-02-27 1999-07-28 东丽株式会社 肺循环改善剂
AU6545498A (en) 1997-03-07 1998-09-22 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
US6030959A (en) * 1997-04-04 2000-02-29 Monsanto Company Gastro-specific prodrugs
JP3217293B2 (ja) * 1997-04-17 2001-10-09 株式会社アールテック・ウエノ 発毛・育毛剤
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
CA2293325C (en) * 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
JP2002501533A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 高眼圧症治療のための眼科用組成物
AU7349298A (en) 1997-06-23 1999-01-04 Pfizer Inc. Prostaglandin agonists
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
AU9374198A (en) 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
WO1999012556A1 (en) 1997-09-08 1999-03-18 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 DOMAIN EPITOPES CAPABLE OF GENERATING NEUTRALIZING ANTIBODIES
WO1999012899A1 (en) 1997-09-09 1999-03-18 The Procter & Gamble Company A process for making prostaglandin f analogs
AUPO907697A0 (en) 1997-09-09 1997-10-02 Day, Robert Edward Chemical supplementation of bone
SK3402000A3 (en) 1997-09-09 2000-12-11 Procter & Gamble Use of a substance primary activating the osteoblastic protein kinase c/intracellular calcium pathways of a subject
US6066751A (en) 1997-09-09 2000-05-23 The Procter & Gamble Company Process for making epoxide intermediates
CA2303763C (en) 1997-09-09 2007-04-24 The Procter & Gamble Company Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
ES2288766T3 (es) 1997-09-09 2008-01-16 Curis, Inc. Efectos sinergicos de morfogenes op/bmp y factores neurotroficos gdnf/ngf.
AU731153B2 (en) 1997-09-09 2001-03-22 Duke University Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists
KR20010023838A (ko) 1997-09-09 2001-03-26 데이비드 엠 모이어 Ｆｐ 작동약으로 유용한 방향족 ｃ16-ｃ20-치환된테트라히드로 프로스타글란딘
WO1999012559A1 (en) 1997-09-09 1999-03-18 The Regents Of The University Of California Inhibition of apoptotis using prosaposin receptor agonists
PL195703B1 (pl) 1997-09-09 2007-10-31 Hoffmann La Roche Zastosowanie polipeptydowego analogu peptydu pokrewnego hormonowi przytarczyc
SK3412000A3 (en) 1997-09-09 2000-12-11 Procter & Gamble Method of increasing bone volume using non-naturally-occurring fp selective agonists
WO1999012558A1 (en) 1997-09-10 1999-03-18 Allegheny University Of The Health Sciences Inhibitors of collagen assembly
NZ502861A (en) 1997-09-10 2001-03-30 Merck & Co Inc Method of treating livestock bacterial respiratory or enteric infections using 9a-azalides
CA2300260C (en) 1997-09-11 2011-05-10 Purdue Research Foundation Galactosidase modified submucosal tissue
ATE285789T1 (de) 1997-09-11 2005-01-15 Us Health Mukosale zytotoxische t-lymphozytenantwort
JP2001515707A (ja) 1997-09-12 2001-09-25 スミスクライン・ビーチャム・コーポレイション 新規原核生物ポリヌクレオチド、ポリペプチドおよびそれらの使用
KR20000068996A (ko) 1997-09-17 2000-11-25 히라이 가쯔히꼬 자궁 경관 숙화제
DE69819350T2 (de) 1997-09-19 2004-07-22 Shionogi & Co., Ltd. Verbindungen mit [2.2.1]bicyclischer molekülstruktur
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
JP2001520999A (ja) 1997-10-28 2001-11-06 アシビ， エルエルシー 女性の性的機能不全の処置
AUPP010397A0 (en) 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
ATE262336T1 (de) 1997-11-14 2004-04-15 United Therapeutics Corp Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
AU1827299A (en) 1997-12-18 1999-07-05 Nathan Earl Scott Prostaglandin e2/f2alpha combination for treating impotence and enhancing sexual arousal
US6099870A (en) 1997-12-18 2000-08-08 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
AU1709699A (en) 1997-12-22 1999-07-12 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
US6436643B1 (en) 1997-12-22 2002-08-20 Unilever Patent Holdings Bv Process for site-directed integration of multiple copies of a gene in a mould
US5955575A (en) 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
KR20010033538A (ko) 1997-12-25 2001-04-25 오노 야꾸힝 고교 가부시키가이샤 ω-시클로알킬-프로스타글란딘 Ｅ２ 유도체
GB2330307A (en) 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
EP1071648A2 (de) 1998-03-13 2001-01-31 Merck Frosst Canada &amp; Co. CARBONSÄUREN UND ACYLSULFONAMIDE, SOLCHE VERBINDUNGEN ENTHALTENDE Gemenge UND BEHANDLUNGSVERFAHREN
CA2324590C (en) 1998-03-31 2006-06-13 The Procter & Gamble Company C11 oxymyl and hydroxylamino prostaglandins useful as fp agonists
ID26699A (id) 1998-03-31 2001-02-01 Procter & Gamble Prostaglandin c11 oksimil dan hidroksilamino yang berguna sebagai obat
US6444840B1 (en) 1998-03-31 2002-09-03 The Procter & Gamble Co. C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists
WO1999061029A1 (fr) 1998-05-25 1999-12-02 Taisho Pharmaceutical Co., Ltd. Agent somnifere
US6458549B2 (en) 1998-06-11 2002-10-01 Winthrop-University Hospital Methods of diagnosing renal salt wasting syndrome and Alzheimer's disease and methods of treating the same
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
WO2000002450A1 (en) 1998-07-08 2000-01-20 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
EP1011728B1 (de) 1998-07-14 2004-12-29 Alcon Manufacturing, Ltd. Polypropylenbasierte behälter für prostaglandin-enthaltende produkte
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
AU5114499A (en) 1998-07-21 2000-02-14 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2002521332A (ja) 1998-07-21 2002-07-16 メルク エンド カムパニー インコーポレーテッド 高眼圧治療用眼薬組成物
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
AU5196699A (en) 1998-08-12 2000-03-06 Kazusa Dna Research Institute Foundation Novel gene and protein pgth encoded thereby
KR20010074981A (ko) 1998-09-14 2001-08-09 우에노 도시오 ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
TR200102561T2 (tr) 1999-03-01 2002-02-21 Pfizer Products Inc. Tiroid alıcı ligantları olarak oksamik asitler ve türevleri
AU763715B2 (en) * 1999-03-05 2003-07-31 Duke University C16 unsaturated fp-selective prostaglandins analogs
KR20010108316A (ko) 1999-03-05 2001-12-07 데이비드 엠 모이어 Ｃ16 불포화된 ｆｐ-선택적 프로스타글란딘 유사체
CA2368242A1 (en) 1999-03-12 2000-09-21 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
IL147771A0 (en) 1999-08-04 2002-08-14 Procter & Gamble Novel 2-decarboxy-2-phosphinico prostaglandin f analogs
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
AU4466901A (en) 2000-03-31 2001-10-08 Toray Industries, Inc. Hair growth or hair formation controlling agents
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
FR2812191B1 (fr) 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812190B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812193B1 (fr) 2000-07-28 2003-10-24 Oreal Utilisation d'antagoniste des recepteurs des prostaglandines ep-2 et/ou ep-4 pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
NZ527408A (en) 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
EP1298223A3 (de) 2001-09-28 2003-07-23 Pfizer Products Inc. Methoden die mit der A-C Wiederholungs-Z-Sequenz stromaufwärts des Aldosereduktasegens in Zusammenhang stehen
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
US20040082013A1 (en) 2002-01-24 2004-04-29 Regan John W Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2alpha activity and methods of treating cancer
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20130041025A1 (en) 2002-02-04 2013-02-14 Allergan, Inc. Compositions and methods for treating hair loss, hair thinning, and hair color loss
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
ES2268327T3 (es) 2002-03-18 2007-03-16 Pfizer Products Inc. Uso de un selectivo de un receptor de ep4 para el tratamiento de enfermedades.
US7186707B2 (en) * 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
GB0208785D0 (en) 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US7320967B2 (en) 2002-04-23 2008-01-22 L'oreal Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
US20030199590A1 (en) 2002-07-25 2003-10-23 Cagle Gerald D Prostaglandin analogues for promotion of hair growth
JP4300833B2 (ja) 2003-03-17 2009-07-22 ソニー株式会社 半導体発光素子の製造方法
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7045634B2 (en) 2003-09-05 2006-05-16 Allergan, Inc. Prostamide receptor antagonists
US20050058614A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US7070768B2 (en) 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
US20050112075A1 (en) 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
WO2005053683A1 (en) 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
US7288029B1 (en) 2005-01-19 2007-10-30 Gkn Driveline North America, Inc. Propshaft with crash-worthiness
EP1812017A2 (de) 2004-10-21 2007-08-01 Duke University Ophthalmologische arzneimittel
GB0506759D0 (en) 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
WO2007123818A2 (en) 2006-04-18 2007-11-01 Nitromed, Inc. Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use
KR101281965B1 (ko) 2006-04-24 2013-07-03 제이에스알 가부시끼가이샤 중합체 및 이를 함유하는 감광성 수지 조성물
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US7868032B2 (en) 2006-10-18 2011-01-11 Allergan, Inc. Prostamide receptor antagonists
JP5095269B2 (ja) 2007-06-05 2012-12-12 北海道エア・ウォーター株式会社 通信システム
US20090018204A1 (en) 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
AU2009340420A1 (en) 2008-10-29 2010-08-26 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010108012A1 (en) 2009-03-18 2010-09-23 Duke University Compositions and methods for promoting nasal patency and treating neurogenic bladder using prostaglandins
CA2769512C (en) 2009-07-29 2019-07-09 Duke University Compositions comprising fp receptor antagonists and their use for inhibiting hair growth

Also Published As

Publication number Publication date
JP2019001828A (ja) 2019-01-10
US20020172693A1 (en) 2002-11-21
JP2014043451A (ja) 2014-03-13
US20170348214A1 (en) 2017-12-07
US8541466B2 (en) 2013-09-24
EP1267807B1 (de) 2005-11-16
CN101897700A (zh) 2010-12-01
DE60115000T2 (de) 2006-08-17
US20200330479A1 (en) 2020-10-22
AU2001253039A1 (en) 2001-10-15
US20140024587A1 (en) 2014-01-23
JP2015134831A (ja) 2015-07-27
ES2252215T3 (es) 2006-05-16
CN101229171A (zh) 2008-07-30
CA2401731C (en) 2007-05-29
JP2017101083A (ja) 2017-06-08
WO2001074315A3 (en) 2002-02-21
US20150238469A1 (en) 2015-08-27
JP2020023579A (ja) 2020-02-13
CA2401731A1 (en) 2001-10-11
US20160106651A1 (en) 2016-04-21
US8906962B2 (en) 2014-12-09
US7388029B2 (en) 2008-06-17
WO2001074315A2 (en) 2001-10-11
US20190175475A1 (en) 2019-06-13
JP2003528899A (ja) 2003-09-30
EP1267807A2 (de) 2003-01-02
US9579270B2 (en) 2017-02-28
CN100384425C (zh) 2008-04-30
ATE309775T1 (de) 2005-12-15
US20050222232A1 (en) 2005-10-06
JP2012046546A (ja) 2012-03-08
US20090286769A1 (en) 2009-11-19
US20080103184A1 (en) 2008-05-01
CA2401731E (en) 2001-10-11
CN1522135A (zh) 2004-08-18

Similar Documents

Publication Publication Date Title
DE60115000D1 (de) Die Verwendung von Prostaglandin F Analoga zur Herstellung von Zusammensetzungen für die Behandlung von Haarausfall.
ATE312587T1 (de) Zusammenseztungen und verfahren zur behandlung von haarausfall unter verwendung von c16-c20 aromatischen tetrahydro-prostaglandinen
AU2001253038A1 (en) Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2001074307A3 (en) Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins
TW200512007A (en) Cosmetic compositions containing fullerene clusters
ATE362387T1 (de) Verwendung eines mutterkrautextrakts zur regulierung der hautalterung
DE69429450D1 (de) Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
ATE294589T1 (de) Fett(öl)haltiges mittel, enthaltend zwiebelextrakt, seine herstellung und seine verwendung zur pflege, vorbeugung oder behandlung von geschädigtem hautgewebe, insbesondere von narben
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
ATE387106T1 (de) Verfahren zur herstellung einer pureezusammensetzung enthaltend eine stabilisierte fruchtmarkzusammensetzung
DE60329180D1 (de) Sebum- und schweissabsorbierendes grundierungsset und entsprechendes mehrstufiges verfahren
DE60308212D1 (de) Verwendung von celluloseperlen zur mattierung der haut
ATE453707T1 (de) Verfahren zur isolierung von mesenchymalen stammzellen des haarfollikels
ES2127490T3 (es) Utilizacion de un aceite rico en acido petroselenico como agente hidratante.
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
ATE349998T1 (de) Creme zur behandlung von sonnengeschädigter haut
DE69110234T2 (de) Verwendung von Vitamin D Verbindungen zur Herstellung einer kosmetischen Zusammensetzung und Anwendung dieser zur Verbesserung der Hautbeschaffenheit.
DE60227701D1 (de) Die verwendung von c-kithemmern zur förderung des haarwuchses
DE60336187D1 (de) Verwendung von einem Extrakt von einem nicht-photosynthetischen faserigen Bakterium zur Beförderung der Herstellung von Superoxid-dismutase
DE69620755D1 (de) Myrteextrakt enthaltendes haarpflegemittel, verfahren zur herstellung und verwendung insbesondere für eine antischuppenbehandlung
ATE259214T1 (de) Parfümzusammensetzung
FR2368269A1 (fr) Compositions en vue d&#39;applications capillaires
RU2003134532A (ru) Мазь для лечения ожогов, гнойных и инфицированных ран различной этиологии и способ лечения ожогов, гнойных и инфицированных ран
DE50000676D1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis
DE69931940D1 (de) Hafestroh enthaltende topische lotion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition